KRAS-targeted therapies, including daraxonrasib and zoldonrasib, show promise in overcoming resistance in cancer treatment, ...

The firm is expecting Phase III readouts this year for its FGFR2b drug bemarituzumab and is advancing a second KRAS inhibitor to the clinic.

The RAS(ON) inhibitor shrunk tumors in around 60 percent of patients with KRAS G12D mutations, according to a study presented at AACR's annual meeting.

A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped responding to chemotherapy, according to a Phase 3 clinical trial ...

Am­gen is the lat­est in a se­ries of bio­phar­ma com­pa­nies to an­nounce a mas­sive new US-based in­vest­ment in man­u­fac­tur­ing in re­sponse to the Trump ad­min­is­tra ...

Biotech company Amgen announced on April 25, 2025, a $900-million expansion of its New Albany manufacturing facility that will add 350 jobs. Biotech company Amgen announced Friday a $900-million ...

NEW ALBANY, Ohio — Biotechnology company Amgen announced a $900 million expansion of its New Albany facility on Friday. The expansion will add 350 new jobs in central Ohio. Several leaders spoke ...

Amgen Inc. will invest $900 million to expand an Ohio manufacturing facility, the latest drug company to promise increased US production as the White House presses forward with tariffs on ...

After unveiling a new drug substance facility in North Carolina in December, Amgen is doubling down on expanding its U.S. production presence with plans for a major upgrade at its plant in central ...

The new study, conducted with support from Amgen Inc., builds on previous research by Dr. Fakih’s team that found sotorasib could be made more effective when combined with panitumumab. City of Hope is ...

Amgen will invest $900 million to expand its New Albany manufacturing facility and add 350 jobs in what is the largest life sciences and pharmaceutical manufacturing expansion in the history of Ohio.